Glioma Stem Cells: Not All Created Equal  by Fine, Howard A.
of the composition of the AR transcrip-
tional complex, and particularly unravel-
ing of the ‘‘modification codes’’ of its crit-
ical components (e.g., Wu et al., 2004),
may serve as a platform for rational design
of PCa therapies.
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A growing body of evidence suggests that only a small subpopulation of malignant glioma cells have true
tumorigenic potential. A study by Pen˜uelas et al. in this issue of Cancer Cell demonstrates that TGF-b can
stimulate self-renewal and inhibit differentiation in a proportion of these glioma-initiating cells.Primary central nervous system (CNS)
malignancies represent an outstanding
model system to explore the cancer stem
cell hypothesis in that tumor- and glioblas-
toma-initiating/stem cells (GICs/GSCs)
have been readily identified in both medul-
loblastomas and glioblastomas (GBMs)
(Hemmati et al., 2003; Singh et al., 2004)
and more is known about the normal devel-
opment of embryonic and adult normal
neural stem cells (NSCs) than any other
tissue-specific stem cell except hemato-
poietic stem cells. In fact, GICs/GSCs have
been shown to have significant similarities
to NSCs through their ability to self-renew,
expression of similar transcriptome pro-
files, and capability of differentiating along
both glial and neuronal lines (Lee et al.,
2006). Comparing the cellular, molecular,
genetic, and epigenetic mechanisms that
underlie basic stem cell properties such
as self-renewal and differentiation should
further elucidate the similarities and differ-
ences between NSCs and GICs/GSCs.
With this as a backdrop, Pen˜uelas et al.
(2009) report in this issue of Cancer Cell
on the effects of transforming growth
factor beta (TGF-b) on GICs/GSCs. TGF-bhas long been considered a potentially
promising therapeutic target in malignant
gliomas, as much through guilt by associa-
tion as because of clear experimental and/
or clinical evidence (Massague´, 2008). The
overexpression of TGF-b commonly seen
in malignant glioma has been variously
implicated in glioma cell proliferation,
migration, decreased apoptosis, and/or
tumor-specific immunosuppression. In a
new twist, Pen˜uelas and coworkers
demonstrate that TGF-b induces GIC/
GSC self-renewal in vitro and enhanced
tumorigenicity in vivo. TGF-b mediates
this activity through activation of and
subsequent binding of a Smad2/3/4
complex to the promoter region of the
leukemia inhibitory factor (LIF) gene. LIF
then activates the JAK-STAT pathway, as
demonstrated by phosphorylation of
STAT3, leading to increased GIC/GSC
tumorigenesis secondary to their increased
self-renewal and decreased differentiation.
Pen˜uelas et al. find that although LIF
enhances NSC self-renewal and partially
inhibits differentiation, TGF-b in contrast
does not induce LIF expression and thus
has no discernable effect on NSCs.Cancer CSo does the different response of GICs/
GSCs versus NSCs to TGF-b represent a
corrupted TGF-b signaling pathway, as is
often seen in other epithelial cancers?
Although TGF-b signals through the
Smad2/3/4 complex in both the GICs/
GSCs and NSCs evaluated by Pen˜uelas
et al., it is known that various cofactors
associated with the Smad complex result
in differential gene expression and repres-
sion in a cell context-dependent manner.
It is therefore plausible that a different set
of tumor-related Smad complex-associ-
ated cofactors accounts for the differential
effects of TGF-b induction on the LIF
promoter in GICs/GSCs compared to
NSCs.
Alternately, it is possible that this TGF-
b-mediated pro-self-renewal phenotype
may not be tumor specific but may
rather be representative of normal sig-
naling within a particular NSC subtype not
utilized in the Pen˜uelas et al. study. It is
well known that the effects of TGF-b and
TGF-b family members (BMPs, activins,
inhibins) on CNS development are cell
intrinsic, cell extrinsic, and context depen-
dent. For example, TGF-b inhibits Wntell 15, April 7, 2009 ª2009 Elsevier Inc. 247
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Neural stem cell-like cells can have different biological outcomes to the activation of the same signaling pathway in a contextually dependent manner based on
both the target cell’s spatial domain and its relative stage of neural stem cell/central nervous system (CNS) development. This complexity, compounded by the
diverse genomic and epigenetic aberrations found in malignant gliomas, could result in biologically different glioma-initiating cells/glioma stem cells from one
tumor to another. Del, deletion; Mut, mutation; Amp, amplification. Developmental stage cartoons and brain image courtesy of Wikimedia Commons; brain image
by Patrick J. Lynch and C. Carl Jaffe.signaling-mediated NSC self-renewal/
proliferation and promotes neuronal differ-
entiation in midbrain-derived NSCs but has
no effects on forebrain-derived NSCs (Falk
et al., 2008). Unlike hematopoiesis, CNS
and NSC development occurs in an intri-
cately choreographed pattern highly spec-
ified in terms of both anterior-posterior/
dorsal-ventral anatomical positioning and
developmental stage timing. The same
transcription factor or signaling pathway
can generate very different biological
consequences depending on the spatial
and chronology-restricted domains of that
particular NSC. It has been shown that
even in adults, NSCs in the subventricular
zone less than 1 mm apart are spatially
restricted relative to fate determination.248 Cancer Cell 15, April 7, 2009 ª2009 ElsThe control NSCs used by Pen˜uelas and
coworkers came from a stage of fetal
CNS development that is largely postproli-
ferative and represented a collection of
total cerebral NSCs. Thus, the phenotype
ofa uniqueTGF-b-responsive anatomically
and temporally specified subpopulation of
NSCs may have been obscured by the
use of this heterogeneous group of NSCs.
The study by Pen˜uelas et al. raises
important questions regarding the
therapeutic potential of TGF-b inhibition
through the demonstration that inhibition
of TGF-band JAK-STAT signaling resulted
in decreased self-renewal and diminished
tumorigenicity of their GICs/GSCs. It is
unclear how prevalent this phenotype will
prove to be among GICs/GSCs fromevier Inc.different GBMs, but since less than half
of the GBMs evaluated by Pen˜uelas et al.
demonstrated increased expression of
TGF-b and/or LIF, it is reasonable to
assume that a large percentage of
GBMs may not have a TGF-b-responsive
GIC/GSC phenotype. This raises the
issue of tumor-specific GIC/GSC hetero-
geneity, for if GICs/GSCs are indeed
derived from precursor cells from various
stages of development and different
anatomical domains, one might expect
significant GIC/GSC heterogeneity from
one tumor to another, a complexity com-
pounded by the unique genetic and epige-
netic alterations found within any given
GBM (TCGA Research Network, 2008)
(Figure 1).
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one tumor-derived GIC/GSC population
to another has profound therapeutic impli-
cations. For example, it was demonstrated
that BMP2/4 induces terminal differentia-
tion in GICs/GSCs, leading to the sugges-
tion that BMP2/4 and/or their agonist
might represent a therapeutic strategy for
gliomas (Piccirillo et al., 2006). When GICs/
GSCs from a larger set of GBMs were eval-
uated, however, it was found that about
20% of GBMs harbor GICs/GSCs with ab-
errant methylation of the BMP receptor 1b
(BMPR1b) promoter converting BMP2/4
from a differentiation agent to a mitogenic
agent (Lee et al., 2008). Thus, not only
would a BMP2/4 agonist fail as a thera-
peutic strategy in these tumors, it might
actually promote GIC/GSC expansion
and tumor growth. In fact, these same
BMPR1b-methylated GICs/GSCs are LIF
unresponsive secondary to the failure of
LIF to induce phosphorylation of STAT3 in
these cells. These GICs/GSCs (and their
parental tumors) are therefore likely to be
refractory to TGF-b and thus are unlikely
to benefit from therapeutic inhibition of
TGF-b and/or the JAK-STAT pathway.
Indeed, in the context ofa veryearly embry-
onic NSC phenotype, STAT3 inhibition is
required for cells to exit symmetric cell divi-
sion and terminally differentiate. Thus, any
therapeutic strategy aimed at blocking theFingering Modulat
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Vitamin A is essential for development and
homeostasis in all vertebrate organisms.
All-trans retinoic acid (all-trans RA) isJAK-STAT pathway in GICs/GSCs derived
from, or with a phenotype similar to, a very
early NSC could actually cause expansion
of the GIC/GSC pool.
Targeting stem cell pathways may ulti-
mately prove to be an effective therapeutic
strategy against malignant gliomas;
however, such pathways may have
dramatically divergent roles in GIC/GSC
populations from different GBMs. Thus,
regardless of whether GICs/GSCs come
from a true NSC or from the dedifferentia-
tion of a mature somatic cell (e.g., astro-
cyte), understanding the divergent sig-
naling mechanisms and phenotypes of
developmentally and anatomically speci-
fied normal NSCs will be vital for under-
standing the unique biology of GIC/GSC
populations from different malignant
tumors (Figure 1). Once those pathways
have been elucidated and validated as
potentially useful therapeutic targets, we
will ultimately need to identify easily as-
sessed surrogate molecular markers of
stem cell pathway activation within each
specific tumor (e.g., BMPR1b, TGF-b/LIF
expression) if we want to use such informa-
tion to guide therapeutic decision-making
for individual patients. The promise of
patient-specific stem cell pathway thera-
peutic targeting will therefore be best real-
ized through an ever greater collaborative
effort between neuroscientists, develop-ors of Retinoic Ac
gnostic Marker fo
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creening strategies can provide new
seases. In this issue of Cancer Cell
is critical for retinoic acid signaling
a key biologically active derivative of
vitamin A that can be isomerized into
9-cisRA and 13-cisRA forms (compounds
Cancer Cmental biologists, cancer researchers,
and clinical scientists.
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